BRUSSELS, June 18 /PRNewswire-FirstCall/ --The first data to show that Neupro® (rotigotine transdermal system) significantly improved wellbeing and daily activities ...

Neupro® (Rotigotine Transdermal System) is approved to treat the signs and symptoms of early and advanced stage idiopathic Parkinson's disease and moderate-to-severe primary restless legs syndrome ...

UCB announced that Neupro (rotigotine transdermal system) is now available as a once-daily patch for the treatment of signs and symptoms of early and advanced stage idiopathic Parkinson’s disease (PD) ...

• Neupro® is a dopamine agonist patch that provides continuous drug delivery for patients with Parkinson's disease and Restless Legs Syndrome2 • Neupro® is now available in 35 countries and over ...

The double-blind, placebo-controlled study showed reduction in total nocturnal systolic blood pressure (:NSBP) elevations connected with periodic limb movements during sleep (:PLMS) and total PLMS in ...

Neupro (rotigotine transdermal system, from UCB and Schwarz Pharma) patches are being recalled due to the formation of rotigotine crystals in the patches. When the drug crystallizes, less drug is ...

We note that Neupro is currently approved in the US and the European Union (EU) for the treatment of the signs and symptoms of early-stage idiopathic PD. The drug is also approved in the EU for the ...

UCB will need to resolve issues concerning crystal formation before regulators in the USA approve the Belgian firm’s Neupro patch for Parkinson’s disease and restless legs syndrome. UCB will need to ...

Please provide your email address to receive an email when new articles are posted on . “Some early attempts have been carried out using dopaminergic drugs, such as L-dopa or selegiline, in samples of ...